Paris, France, Dec. 01, 2016 (GLOBE NEWSWIRE) -- Paris, 1 st of December 2016, 6.30pmAB Science will present phase 3 results in severe systemic mastocytosis at the Journées Dermatologiques de Paris 2016, organized by the French Society of DermatologyImportant step in the rapid treatment of patients in case of masitinib marketing authorizationAB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), today announced that results from its phase 3 trial in severe systemic mastocytosis have been selected for an oral presentation at the congress 'Journées Dermatologiques de Paris 2016', organized by the French Society of Dermatology (December 6 - 10, 2016, Paris, France). The Journées Dermatologiques de Paris is the annual congress of the French Society of Dermatology. This congress hosts more than 5,000 professionals from all over the world with an interest in dermatology, with a program that promotes research and education. Abstracts were selected by the selection committee of the Congress (three independent readers and one Jury plenary meeting), on the basis of their scientific quality. The abstract for this presentation will be published in the scientific journal 'Annales de Dermatologie et de Vénéréologie' (Volume 143, Issue 12, Supplement, December 2016, Pages S188-S189). Professor Olivier Hermine, President of the Scientific Committee of AB Science and coordinator of the Reference Center for Mastocytosis (CeReMast, Paris, France), will deliver this oral presentation on Thursday, 8 th December. Professor Olivier Hermine said: "For indolent forms of mastocytosis, the diagnosis of the disease is often first made by dermatologists, since both cutaneous and systemic forms of mastocytosis are typically associated with cutaneous symptoms, leading to a dermatologist consultation. It is therefore very important that dermatologists are aware of the results for masitinib in this indication. We are very pleased with the interest shown by the dermatologist community, because their intervention represents an important step in the rapid treatment of patients in case of possible future marketing authorization for masitinib in this indication".